Government of Canada investments of more than $2.1B in 36 projects in the biomanufacturing, vaccine and therapeutics ecosystem, strengthening domestic pandemic response capabilities and life science innovation
View the information on an interactive map
National
The Government of Canada has invested in research projects across Canada through important granting partners like the Canadian Institutes for Health Research. For the complete list of investments in research initiatives please consult the Government of Canada investments in the biomanufacturing, vaccine and therapeutics ecosystem.
Alberta
Total investments
$95,414,000
Numbers of projects
3
Number of investments
4
Description of projects
Canadian Critical Drug Initiative (Edmonton, AB)
Canadian Critical Drug Initiative (Edmonton, AB)
March 17, 2023: $80.5 million over five years from Prairies Economic Development Canada (PrairiesCan) to increase and support the initiative's integrated research, development, and manufacturing activities in Edmonton that will strengthen Alberta's biomedical sector and increase the domestic production of critical medicines.Related link:
Entos Pharmaceuticals (Edmonton, Alberta)
- October 23, 2020: $5.0 million through NRC‑IRAP for phase 1 clinical trials of its Covigenix VAX-001 vaccine candidate
Related link:
Providence Therapeutics and Northern RNA Inc. (Calgary, Alberta)
Providence Therapeutics and Northern RNA Inc.
- January 21, 2021: Up to $5 million through the Next Generation Manufacturing Canada supercluster, to expand their operations in Calgary to design and manufacture COVID-19 vaccines and build a pipeline of mRNA vaccines
- October 23, 2020: $4.9 million through NRC-IRAP for phase 1 clinical trials of its PTX-COVID19-B mRNA vaccine candidate
Related links:
Atlantic Canada
Total investments
$73,700,000
Numbers of projects
3
Number of investments
5
Description of projects
BIOVECTRA (Charlottetown, PEI)
- November 18, 2021: $39.8 million through the Strategic Innovation Fund (SIF) to build a state-of-the-art facility in Prince Edward Island and reconfigure their facilities in Nova Scotia.
IMV Inc. (Dartmouth, Nova Scotia)
- October 23, 2020: $5.4 million through NRC-IRAP for phase 2/3 clinical trials of its DPX-COVID19 vaccine candidate
- August 5, 2020: $2.5 million through the Next Generation Manufacturing Canada supercluster to advance clinical development of its vaccine candidate for the prevention of COVID-19 infection.
- July 22, 2020: $1 million from the Atlantic Canada Opportunities Agency to support the pre-clinical activities necessary to meet the requirements for a clinical trial application to Health Canada
Related links:
PEI BioAlliance (Charlottetown, PEI)
- February 10, 2023: $25M from the Atlantic Canada Opportunities Agency toward the design and construction of the PEI BioAlliance BioAccelerator, a new biomanufacturing facility on Prince-Edouard-Island
Related links:
British Columbia
Total investments
$539,000,764
Numbers of projects
7
Number of investments
8
Description of projects
AbCellera Biologics (Vancouver, British Columbia)
- May 3, 2020: $175.6 million through the Strategic Innovation Fund (SIF) toward its antibody therapy research and the construction of an antibody production facility
- May 24, 2023: $225 million through the Strategic Innovation Fund (SIF) to create a state-of-the-art biotech campus equipped with a new preclinical antibody development facility and make significant upgrades to its existing facilities in Vancouver
Related links:
adMare BioInnovations (Vancouver, British Columbia)
- March 30, 2022: Up to $92 million provided in the 2021 Federal Budget to prepare Canada for future pandemics and health emergencies by supporting research and development (R&D), company creation, scale-up, and training activities in the biomanufacturing and life sciences sector.
Bold Therapeutics (Vancouver, British Columbia)
- December 18, 2020: Up to $289,032 through NRC-IRAP for a project to prepare preclinical efficacy data in live SARS-CoV-2 (COVID‑19) and support preparation for clinical trials and manufacturing of its BOLD-100 investigational therapy to treat patients with viral infections, including COVID‑19
Related link:
Precision NanoSystems Inc. (Vancouver, British Columbia)
- February 2, 2021: $25.1 million through the Strategic Innovation Fund (SIF) to support a $50.2 million project to expand Canada's capabilities in the production of ribonucleic acid (RNA) vaccines and future genetic medicines, while enhancing Canada's biomanufacturing capacity
- October 23, 2020: Up to $18.2 million through the Strategic Innovation Fund (SIF) to help advance the development of a COVID‑19 vaccine candidate through preclinical studies and clinical trials
Related links:
Symvivo (Burnaby, British Columbia)
- October 23, 2020: $2.8 million through NRC‑IRAP to advance its bacTRL-Spike oral DNA vaccine candidate in preclinical and phase 1 clinical trials
Qu Biologics (Vancouver, British Columbia)
- December 18, 2020: Up to $109,764 through NRC‑IRAP for a project to provide proof-of-concept evidence for the safety and efficacy of a preventive treatment, as well as therapeutic use of a treatment, to protect the lungs and prevent serious COVID-19 infection
Related links:
Ontario
Total investments
$774,035,000
Numbers of projects
10
Numbers of investments
11
Description of projects
Arch Biopartners (Toronto, Ontario)
- December 15, 2020: Up to $6.7 million through the Strategic Innovation Fund (SIF) to advance its lead drug candidate as a treatment for organ inflammation in severe cases of COVID-19
Related link:
Edesa Biotech (Markham, Ontario)
- February 2, 2021: Up to $14 million through the Strategic Innovation Fund (SIF) which is developing a monoclonal antibody therapy (EB05) as a treatment for Acute Respiratory Distress Syndrome, the leading cause of death among COVID‑19 patients
Related link:
Hypermabs Inc. (Toronto, Ontario)
Hypermabs Inc.
- December 18, 2020: Up to $1.9 million through NRC‑IRAP to support the development of their FB100 therapeutic, a novel treatment for COVID-19 survivors with lung fibrosis
Mannin Research Inc. (Toronto, Ontario)
- December 18, 2020: Up to $1.7 million through NRC‑IRAP to support the development of methodology for purification and pre-clinical testing of a therapeutic to prevent vascular leakage in Acute Respiratory Distress Syndrome
Novocol Pharmaceutical of Canada (Cambridge, Ontario)
Novocol Pharmaceutical of Canada
- March 16, 2021: Up to $32.7 million through the Strategic Innovation Fund (SIF) to expand their biomanufacturing facilities in Cambridge, Ontario
Related links
Resilience Biotechnologies Inc. (RBI) (Mississauga, Ontario)
Resilience Biotechnologies Inc. (RBI)
- May 18, 2021: Up to $199.16 million through the Strategic Innovation Fund (SIF) to increase its manufacturing and fill-finish capacity for a number of vaccines and therapeutics, including for those that use novel technology such as mRNA and that are now being deployed to fight COVID-19.
Related links
Sanofi Pasteur Limited (Sanofi) (Toronto, ON)
- March 31, 2021: Up to $415 million through the Strategic Innovation Fund (SIF) to support building an end-to-end influenza vaccine manufacturing facility.
Related link:
Stem Cell Network (Ottawa, Ontario)
- May 12, 2022: Over $19.5 million through the Stem Cell Network for 32 research projects and clinical trials across Canada focused on rare and chronic diseases. This funding is part of the $45 million federal investment over three years for the Stem Cell Network to support stem cell and regenerative medicine research.
- April 23, 2020: Over $675,000 through the Stem Cell Network to support two new research projects and one clinical trial. The clinical trial will evaluate the safety of a potential cell therapy to reduce the impacts and severity of acute respiratory distress associated with COVID‑19, and the two projects will generate critical information about how cells in the airway and brain are affected by the virus
Related link:
Variation Biotechnologies Inc. (VBI) (Ottawa, Ontario)
Variation Biotechnologies Inc. (VBI)
- August 5, 2020: Up to $56 million through the Strategic Innovation Fund (SIF) to support clinical trials for a COVID-related vaccine candidate
Related link:
Vasomune Therapeutics Inc. (Toronto, Ontario)
- December 18, 2020: Up to $1.2 million through NRC‑IRAP to support phase 1 clinical trials of its AV-001 drug candidate which will be used to treat patients with Acute Respiratory Distress Syndrome resulting from COVID‑19.
Quebec
Total investments
$476,506,796
Numbers of projects
12
Number of investments
12
Description of projects
Biodextris Inc. (Laval, Quebec)
- October 23, 2020: $1.3 million through NRC‑IRAP for preclinical development of its nasal COVID‑19 vaccine candidate
Related link:
Glycovax Pharma (Montréal, Quebec)
- October 23, 2020: $4.0 million through NRC‑IRAP for phase 1 clinical trials of its COVID-19 vaccine candidate
Related link:
Immune Biosolutions (Sherbrooke, Quebec)
- March 16, 2021: Up to $13.44 million to help through the Strategic Innovation Fund (SIF) to develop and advance its therapeutic candidate from pre-clinical studies up to Phase II clinical trials
Related link:
JN Nova Pharma (Montréal, Quebec)
- December 18, 2020: Up to $4,609,000 through NRC‑IRAP to assist in the development of a proprietary drug to block coronavirus infection, while reducing the impacts of the disease in patients exhibiting COVID‑19 symptoms so they may recover faster
Related link:
Jubilant HollisterStier (Kirkland, Quebec)
- March 16, 2023: $23.8 million through the Strategic Innovation Fund to increase its capacity for a variety of vaccines, including mRNA and its annual fill and finish capacity.
Related links:
- The Government of Canada continues to invest in domestic vaccine production
KABS Laboratories Inc. (Saint-Hubert, Quebec)
- March 16, 2021: Up to $54.2 million through the Strategic Innovation Fund (SIF), for the expansion of its Saint‑Hubert facility and establishing a new facility in Val-des-Sources, both in Quebec
Related link:
Laurent Pharmaceuticals (Montréal, Quebec)
- December 18, 2020: Up to $4,166,796 through NRC-IRAP for the clinical development of its LAU-7b antiviral and inflammation controlling therapy for COVID-19 infections
Related link:
Medicago (Québec, Quebec)
- October 23, 2020: Up to $173 million through the Strategic Innovation Fund (SIF) to advance its virus-like particle vaccine candidate and establish a large-scale biomanufacturing facility
Related link:
Moderna (Quebec)
- April 29, 2022: Leading COVID-19 vaccine developer Moderna will build and operate a state-of-the-art mRNA vaccine production facility in Quebec. Once completed in 2025, the facility will have the capacity to produce up to 100 million mRNA vaccine doses per year.
Novavax (Montréal, Quebec)
- February 2, 2021: Signing a memorandum of understanding with Novavax to pursue production of its COVID‑19 vaccine at the NRC's Biologics Manufacturing Centre, once both the vaccine candidate and the facility receive the required Health Canada approvals
Related link:
NRC Royalmount (BMC) (Montréal, Quebec)
- August 31, 2020: $126 million to build a new Biologics Manufacturing Centre at its Royalmount site in Montréal. Once built, the new centre will be capable of large-quantity, end-to-end production of vaccines—approximately 2 million doses per month, depending on the vaccine candidate
NRC Royalmount - Clinical Trial Material Facility (CTMF) (Montréal, Quebec)
NRC Royalmount - Clinical Trial Material Facility (CTMF)
- $44 million to establish a Good Manufacturing Practices (GMP) compliant clinical trial material facility at its Royalmount site in Montréal. Once complete, this permanent facility will be able to produce small-batch clinical trial materials from cell-based biologics production, including platforms such as viral vector, protein subunit, virus-like particles and other recombinant proteins
Saskatchewan
Total investments
$106,500,000
Numbers of projects
1
Number of investments
5
Description of projects
Vaccine and Infectious Disease Organization (VIDO) (Saskatoon, Saskatchewan)
Vaccine and Infectious Disease Organization (VIDO)
- April 23, 2021: $59.2 million, through Western Economic Diversification Canada to support the development of its COVID-19 vaccine candidates and expand its facility in Saskatoon.
- December 11, 2020: $35 million, through Western Economic Diversification Canada to accelerate development of its COVID‑19 vaccine candidate and enhance its vaccine manufacturing facilities to the good manufacturing practices standards required for human vaccines
- November 6, 2020: $300,000 through the Canada Foundation for Innovation (CFI) for new imaging equipment to help understand COVID-19 infection
- March 6, 2020: $1 million through the Canadian Institutes of Health Research federal rapid research funding initiative for research projects aimed at addressing COVID-19
- March 1, 2020: $11 million through the Canada Foundation for Innovation (CFI) in operation funding
Related links:
Planning for the future
In addition to biomanufacturing capacity, our investments will ensure that, in the long term, Canada has the talent, a research and development pipeline, robust SMEs and security across the supply chain to support a dynamic and growing biologics manufacturing and innovation ecosystem.
Work is under way to assess current and ongoing needs in the biomanufacturing sector and to find ways to complement recent government investments—such as those made through the Strategic Innovation Fund (SIF) and the National Research Council of Canada's Industrial Research Assistance Program (NRC IRAP).
Complete list of Government of Canada investments in COVID-19 vaccines and biomanufacturing capacity: